From: A model building exercise of mortality risk for Taiwanese women with breast cancer
Pathological Data | |||
---|---|---|---|
Risk factors | Mortality(%) | Odds Ratio | P-value |
Pathological report | <.001 (a v.s. c) | N.S. | |
0.532 (b v.s. c) | N.S. | ||
Others (a) (n = 138) | 0 | ||
Invasive ductal carcinoma (b) (n = 966) | 66 (6.8%) | ||
Invasive lobular carcinoma (c) (n = 33) | 4 (12.1%) | ||
Tumor grade | 2.172 | <.0001 * | |
III (n = 234) | 27 (11.5%) | ||
II (n = 431) | 24 (5.6%) | ||
I (n = 294) | 8 (2.7%) | ||
ER/PR | 1.99 | 0.009 * | |
(-, -), (-, +), (+, -) (n = 583) | 47 (8.1%) | ||
(+, +) (n = 545) | 23 (4.2%) | ||
Her-2/Neu | 2.125 | 0.014* | |
+++ (n = 181) | 18 (9.9%) | ||
-, +, ++ (n = 668) | 33 (4.9%) | ||
EIC | 2.036 | 0.032 * | |
Absent (n = 590) | 46 (7.8%) | ||
Present (n = 301) | 12 (4.0%) | ||
LTE | 2.856 | 0.0004 * | |
Present (n = 501) | 46 (9.2%) | ||
Absent (n = 468) | 16 (3.4%) | ||
HBsAg | 1.22 | N.S. | |
+ (n = 124) | 8 (6.5%) | ||
- (n = 598) | 32 (5.4%) | ||
HCVAb | 1.103 | N.S. | |
+ (n = 50) | 3 (6%) | ||
- (n = 658) | 36 (5.5%) | ||
R/T | 1.002 | N.S. | |
Yes (n = 581) | 39 (6.7%) | ||
No (n = 552) | 31 (5.6%) | ||
Anti-hormone therapy | 1.002 | N.S. | |
No (n = 228) | 14 (6.2%) | ||
Yes (n = 909) | 56 (6.2%) | ||
Tumor size | 2.579 | <.0001 * | |
T4 (n = 57) | 10 (17.5%) | ||
T2 or T3 (n = 595) | 45 (7.6%) | ||
Tis or T1 (n = 485) | 15 (3.1%) | ||
Node | 4.053 | <.0001 * | |
N3 (n = 81) | 23 (28.4%) | ||
N1 or N2 (n = 377) | 31 (8.2%) | ||
N0 (n = 677) | 16 (2.4%) | ||
Chemotherapy | 0.061 (a v.s. c) | <0.0001* | |
0.391 (b v.s. c) | 0.009 * | ||
No (a) (n = 327) | 4 (1.2%) | ||
Yes (b) (n = 745) | 55 (7.4%) | ||
Abandonment or Refusal (c) (n = 65) | 11 (18%) |